176 related articles for article (PubMed ID: 8202717)
1. Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
Markman M
Semin Oncol; 1994 Apr; 21(2 Suppl 2):17-9; quiz 20, 58. PubMed ID: 8202717
[TBL] [Abstract][Full Text] [Related]
2. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
Markman M; Reichman B; Hakes T; Rubin S; Lewis JL; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
[TBL] [Abstract][Full Text] [Related]
3. Current status of intraperitoneal therapy for ovarian cancer.
Markman M
Curr Opin Obstet Gynecol; 1993 Feb; 5(1):99-104. PubMed ID: 7678757
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of advanced ovarian cancer.
Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
[TBL] [Abstract][Full Text] [Related]
5. An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
Markman M
Cancer J; 2009; 15(2):105-9. PubMed ID: 19390303
[TBL] [Abstract][Full Text] [Related]
6. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Gynecol Oncol; 1997 Jun; 65(3):434-6. PubMed ID: 9190971
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal cisplatin therapy in ovarian cancer: comparison with standard intravenous carboplatin and paclitaxel.
Ozols RF; Bookman MA; du Bois A; Pfisterer J; Reuss A; Young RC
Gynecol Oncol; 2006 Oct; 103(1):1-6. PubMed ID: 16904166
[No Abstract] [Full Text] [Related]
8. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
[TBL] [Abstract][Full Text] [Related]
9. Understand the benefits and risks of intraperitoneal therapy for advanced ovarian cancer.
Oestreicher P
ONS Connect; 2007 Apr; 22(4):24-5. PubMed ID: 17477008
[No Abstract] [Full Text] [Related]
10. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
11. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
13. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
14. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.
Muggia FM; Groshen S; Russell C; Jeffers S; Chen SC; Schlaerth J; Curtin J; Morrow CP
Gynecol Oncol; 1993 Aug; 50(2):232-8. PubMed ID: 8375739
[TBL] [Abstract][Full Text] [Related]
16. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
17. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma.
Beddoe AM; Dottino PR; Cohen CJ
Mt Sinai J Med; 1993 Sep; 60(4):311-6. PubMed ID: 8232377
[TBL] [Abstract][Full Text] [Related]
19. Intraperitoneal therapy of ovarian cancer.
Markman M
Semin Oncol; 1998 Jun; 25(3):356-60. PubMed ID: 9633848
[TBL] [Abstract][Full Text] [Related]
20. Intraperitoneal therapy for ovarian cancer: why has it not become standard?
Rowan K
J Natl Cancer Inst; 2009 Jun; 101(11):775-7. PubMed ID: 19470952
[No Abstract] [Full Text] [Related]
[Next] [New Search]